(Q37776226)

23 August 2017

1 reference

title

Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine (English)

1 reference

23 August 2017

1 reference

1 reference

2

Pierre Michetti

1 reference

23 August 2017

Christopher Sj Probert

3

object named as

Chris S. Probert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665988

12 June 2024

author name string

Pia Munkholm

1

1 reference

23 August 2017

Margarita Elkjaer

4

1 reference

23 August 2017

Philippe Marteau

5

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20665988

12 June 2024

publication date

1 August 2010

1 reference

full work available at URL

23 August 2017

http://journals.lww.com/00042737-201008000-00002

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

European Journal of Gastroenterology and Hepatology

12 June 2024

published in

1 reference

23 August 2017

volume

22

1 reference

23 August 2017

issue

8

1 reference

23 August 2017

page(s)

912-916

1 reference

Course of ulcerative colitis: analysis of changes in disease activity over years

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

12 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis

12 June 2024

3

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

The Role of Quality of Care in Health-related Quality of Life in Patients with IBD

12 June 2024

4

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

IBD patients need in health quality of care ECCO consensus

12 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Review article: what do patients with inflammatory bowel disease want for their clinical management?

12 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Ulcerative colitis and irritable bowel syndrome: relationships with quality of life

12 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Welcome to the journal of Crohn's & colitis

12 June 2024

8

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

European evidence-based Consensus on the management of ulcerative colitis: Current management

12 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis

12 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

12 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis

12 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis

12 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis

12 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

12 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

12 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

12 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis

12 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

12 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis

12 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.

12 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

12 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study

12 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis

12 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis

12 June 2024

30

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Review article: maintenance therapy in patients with ulcerative colitis

12 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study

12 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.

12 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

12 June 2024

34

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease

12 June 2024

35

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

12 June 2024

36

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies

12 June 2024

37

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

A new rapid home test for faecal calprotectin in ulcerative colitis

12 June 2024

39

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial

12 June 2024

41

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis

12 June 2024

42

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

12 June 2024

43

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial

12 June 2024

44

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

12 June 2024

45

1 reference

https://api.crossref.org/works/10.1097/MEG.0B013E32833944BF

12 June 2024

Identifiers

1 reference

23 August 2017

1 reference